All I'm saying is that under the circumstance it seems odd that the results for the control arm was an outlier. Although the primary endpoint result wasn't statistically significant, I wouldn't consider this trial a failure. I think the survival results will help determine what happens with this indication.
Learning from failure can be good. It seems that making some changes to bavi's pancreatic trial protocol could bring some meaningful results.
News 
Market Data 
Discover 
AI
